References
- Hulse GK, Stalenberg V, McCallum D, Smit W, O’neil G, Morris N et al. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release 2005;108:43–55.
- Smith A, Hunneyball IM. Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986;30:sssss.
- Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998;50:1–8.
- Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 2003;69:263–272.
- Gong ZH, Su RB, Yan LZ, Liu YS, Qing BY. The reports of preventing relapse in 2000. Chin J Drug Depend 2001;10:4–6.
- Zhao WL, Gong ZH, Liang JH. A new buprenorphine analogy, thenorphine, inhibits morphine-induced behavioral sensitization in mice. Acta Pharmacol Sin 2004;25:1413–1418.
- Yu G, Yue YJ, Cui MX, Gong ZH. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine. J Pharmacol Exp Ther 2006;318:282–287.
- Yang Y, Gao Y. Preparation and in vivo evaluation of thienorphine-loaded PLGA microspheres. Pharmazie 2010;65:729–732.
- Wu XG, Li G, Gao YL. Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design. Chem Pharm Bull 2006;54:977–981.
- Fu X, Ping Q, Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J Microencapsul 2005;22:57–66.
- Fu XD, Gao YL, Ping QN, Ren T. Preparation and in vivo evaluation of huperzine A-loaded PLGA microspheres. Arch Pharm Res 2005;28:1092–1096.
- Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison–statistics and analysis of the similarity factor, f2. Pharm Res 1998;15:889–896.
- Bittner B, Mader K, Kroll C. Tetracycline-HCl-loaded poly(D,L-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Control Rel 1999;59:23–32.
- China Pharmacopoeia. 2010. Attachment, 103–107.
- Raman C, Berkland C, Kim K, Pack DW. Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. J Control Release 2005;103:149–158.
- International Conference on Harmonization (ICH) harmonized tripartite guideline. 2005. Impurities: Guideline for Residual Solvents, Q3C (R3).
- Bodmeier R, McGinity JW. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. I. Methods and morphology. J Microencapsul 1987;4:279–288.
- Zhu KJ, Jiang HL, Du XY. Preparation and characterization of hcG-loaded polylactide or poly (lactide-coglycolide) microspheres using a modified W/O/W emulsion solvent evaporation technique. J Microencapsul 2001;18:247–260.
- Bodmeier R, Oh KH, Chen H. The effect of the addition of low weight poly(d,l-lactide) on drug release from biodegradable poly(d,l-lactide) drug delivery systems. Int J Pharm 1989;51:1–8.
- Boury F, Marchais H, Proust JE, Benoit JP. Bovine serum albumin release from poly(α-hydroxy acid) microspheres: effect of polymer molecular weight and surface properties. J Control Rel 1997;45:75–86.
- O’Donnell PB, McGinity JW. Preparation of microspheres by the solvent evaporation technique. Advanced Drug Delivery Reviews 1997;28:25–42.
- Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 2005;102:313–332.
- Su Z, Sun F, Shi Y, Jiang C, Meng Q, Teng L et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Chem Pharm Bull 2009;57:1251–1256.